Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis

Abstract Background and purpose In relapsing–remitting multiple sclerosis (RRMS), analyses from observational studies comparing dimethyl fumarate (DMF) and teriflunomide showed conflicting results. We aimed to compare the effectiveness of DMF and teriflunomide in a real‐world setting, where both drugs are licensed as first‐line therapies for RRMS. Methods We included all patients who initiated DMF or teriflunomide between 2013 and 2022, listed in the Swiss National Treatment Registry. Coarsened exact matching was applied using age, gender, disease duration, baseline Expanded Disability Status Scale (EDSS) score, time since last relapse, and relapse rate in the previous year as matching variables. Time to relapse and time to 12‐month confirmed EDSS worsening were compared using Cox proportional hazard models. Results In total, 2028 patients were included in this study, of whom 1498 were matched ( DMF : n = 1090, 69.6% female, mean age 45.1 years, median EDSS score 2.0; teriflunomide : n = 408, 68.9% female, mean age 45.1 years, median EDSS score 2.0). Time to relapse and time to EDSS worsening was longer in the DMF than the teriflunomide group (hazard ratio 0.734, p = 0.026 and hazard ratio 0.576, p = 0.003, respectively). Conclusion Analysis of real‐world data showed that DMF treatment was associated with more favorable outcomes than teriflunomide treatment.